

CLINICAL
TRIALS
ONTARIO



Speaker Bios & Innovation Showcase



**CTO Conference: Clinical Trials
Today and Tomorrow**

March 27-28, 2019

Speakers



John Adams

Board Chair of the Best Medicines Coalition; Co-founder, President & CEO of Canadian PKU and Allied Disorders

Mr. Adams is a graduate of York University; worked as a reporter for The Globe and Mail; chief of staff to a Cabinet Minister in Ontario; elected three times to Toronto City Council, serves as Budget Chief and Acting Mayor; and served as a trustee of Canada's largest hospital, the University Health Network.



John-Peter Bradford

CEO, Life-Saving Therapies Network

John-Peter is a cancer survivor, caregiver and is passionate about his work on issues of cancer research, healthcare policy and treatment delivery. He is co-founder of the patient-led Life-Saving Therapies Network (LSTN), an international group of patients, oncologists, researchers, regulators, ethicists, HTA specialists, and industry representatives that aims to create faster, less expensive access to better therapies for lethal diseases. He is also a Co-Chair of the Advocacy Committee of Lung Cancer Canada, and served as a member of the Research Advisory Group of the Canadian Partnership Against Cancer

and the Cancer Care Advisory Committee of the Ottawa Regional Cancer Foundation. His book, *Journeys in Cancerland*, with Lisa Newman, was published in 2012. John-Peter is a Fellow of the Institute of Certified Management Consultants of Ontario (FCMC). He holds a B.A. in Psychology, an M.A. in Experimental Psychology, an A.B.D. in Experimental Psychology (Psychopharmacology) and a PhD. in Psychology and Community Services.



Jennifer Chan

Vice President, Policy and External Affairs, Merck Canada Inc.

As Vice President, Policy and External Affairs, Jennifer Chan is responsible for the company's team of government relations and public affairs specialists. Prior to this role, she held the position of Vice President, Policy and Communications at Merck Canada. A native of Montreal, Jennifer began her career in academic research before joining Schering-Plough as a Clinical Research Associate. Since then, she has worked in various areas of the business, primarily in Regulatory Affairs, Specialty Services and Medical Affairs. Jennifer is a member of the Board of Directors for the Institute of Health Economics in

Alberta, the Quebec Consortium for Drug Discovery, the Quebec Network for Personalized Health Care, and Life Sciences Ontario. Jennifer holds a Bachelor of Science degree in physiology and a Master of Science degree in pharmacology and therapeutics, both from McGill University in Montreal.



Dr. Mark Clemons

Clinical Investigator, Ottawa Hospital Research Institute

Dr. Mark Clemons graduated from the University of Newcastle upon Tyne, U.K. (B.Med.Sci; MB BS). He completed his post-doctoral training in internal medicine and medical oncology at the Hammersmith Hospital, London; Christie Hospital, Manchester (MSc, Oncology; MD, Oncology) and at the Princess Margaret Hospital, Toronto. He is a Clinical Investigator at the Ottawa Hospital Research Institute (Cancer Therapeutics Program), staff medical oncologist (Ottawa Hospital Cancer Centre) and Professor of Medicine

(University of Ottawa). He is the recipient of multiple peer-reviewed research grants and is widely published in the field of breast cancer management. His publications also reflect eclectic topics: retirement planning, excessive oncologist travel, oncologist quality of life and preventing spam. His current research vision is to remove many of the barriers that lead the development of multiple standard of care therapies with very little data to actually show which treatment is best in the real-world setting.



Patrick Clifford

Director of Research and Innovation, Southlake Regional Health Centre

Patrick Clifford is the Director of Research and Innovation at the Research Institute of Southlake Regional Health Centre and CreateIT Now, Southlake's health innovation centre. Patrick is responsible for oversight of research operations and infrastructure (including the REB), and advancing innovation, commercialization and culture building through strategic collaborations. Patrick is leading the development and implementation

of Southlake's research agenda and advancing the innovation and commercialization strategy which includes growing partnerships and collaborations with private sector ventures wishing to test and/or validate health focused technologies with Southlake clinicians. Patrick is also engaged in Southlake's leading role in innovative, outcome-based procurement practices. Patrick brings 32 years of health care experience in acute care to his current role. He holds an MSW, a BA, BSW and BEd and continues to practice as a clinician on a periodic basis in an emergency mental health setting.



Patrick Cupido

Past Chair, CATIE (Canadian Aids Treatment Information Exchange)

Patrick spent most of his professional career with the Office of the Auditor General of Ontario.

In the years since learning he was HIV+ in 1989, he has also applied his accounting and management experience as executive director of the AIDS Committee of Cambridge, Kitchener, Waterloo and Area, and on the boards of CATIE, Fife House Foundation, the Ontario AIDS Network and the Canadian Treatment Action Council. His interests (and the volunteer positions through which he has pursued them) include

community engagement and ethics in research (Ontario HIV Treatment Network Cohort Study Governance Committee, Canadian HIV Trials Network Community Advisory Committee), treatment side effects (Health Canada's Expert Advisory Committee on the Vigilance of Health Products), and new prevention technologies (Canadian HIV Vaccines Plan Steering Committee).



Beth Dangerfield

Family Partnership Specialist, Holland Bloorview Kids Rehabilitation Hospital

Before becoming an employee, Beth was a volunteer Family Leader. She was a member of the Dear Everybody campaign Committee and acted as Family as Faculty, sharing her lived experience to committees and teams across the hospital and the Bloorview Research Institute. In 2018, Beth helped to plan the annual Teaching and Learning Day event. Beth is a certified Junior/Intermediate teacher with the Ontario College of Teachers, with additional training and 10 years of experience in Special Education and

teaching as a second language. Beth is the parent of a child with a disability and complex medical condition. She is passionate about working in pediatric health care to bring about meaningful change for kids and youth and their families who are affected by disability and rare disease. Beth writes about disability and rare disease parenting, volunteers with Girl Guides of Canada and is a lay reviewer for the Rare Disease Foundation Microgrant Program.



Jason Field

President and CEO of Life Sciences Ontario

Dr. Jason Field is the President and CEO of Life Sciences Ontario (LSO), the industry voice for the life sciences sector in Ontario. Jason obtained his PhD in Chemistry from the University of Massachusetts and his undergraduate degree from the University of Waterloo. Following graduate school, Jason returned to Ontario and worked in the pharmaceutical industry as a research scientist developing scalable manufacturing processes of active pharmaceutical ingredients.



Sharon Gabison

Co-chair of the Research and Family Engagement Committee and Family Leader at Holland Bloorview Kids Rehabilitation Hospital

Sharon Gabison has sat on several projects at the Holland Bloorview Kids Rehabilitation Hospital as a family research partner. Currently, she is working as a Post-Doctoral Research Fellow with an interdisciplinary team at Toronto Rehab – UHN, developing technologies to prevent pressure injuries and support home caregivers. She has over 20 years of clinical experience as a Physical Therapist. As a family partner, researcher and

advocate, she is passionate about engaging patients and families in research to bridge the gap between research and knowledge translation in order to improve the lives of individuals and their families living with disabilities.



Giles Gherson

Deputy Minister, Red Tape and Regulatory Burden Reduction, Cabinet Office

Giles Gherson was appointed Deputy Minister of Red Tape and Regulatory Burden Reduction, Cabinet Office, in June 2018. Previously, he was appointed Deputy Minister of Research, Innovation and Science, and Deputy Minister of Economic Development and Growth in September 2014, and concurrently Deputy Minister Responsible for Small Business in January 2017. Giles's first appointment was Deputy Minister of Communications and Associate Secretary of the Cabinet, and he has been a leading force in modernizing

government communications, including introducing social media. In July 2008, Giles was appointed Deputy Minister of Policy and Delivery and Associate Secretary of the Cabinet, and in November 2011 he became Deputy Minister of Consumer Services. Prior to joining the Ontario government, Giles was, successively, editor-in-chief of the Toronto Star, editor of the Globe and Mail's Report on Business, and editor-in-chief of the Edmonton Journal. He has worked as an editor, reporter and columnist in Washington, Ottawa and Edmonton. During the mid-1990s, Giles served as principal secretary for social security reform in the federal Department of Human Resources Development.



Eric Gildenhuyts

Vice-President of Business Development, Deep 6 AI

Eric began his career by co-founding and selling a software company to Optio Software, helping guide Optio to a successful IPO by expanding into the healthcare market and launching its European headquarters. During his career, Eric has been helping software and professional services firms such as PwC all over the world in shifting the paradigm of their business development culture, resulting in new contracts worth \$100+ million. He is a frequent speaker and works closely with hospitals, pharma companies and research institutes on patient recruitment programs.



Lisa Goos

Director of Clinical Research Services, The Hospital for Sick Children

Dr. Goos received her Ph.D. in cognitive psychology from York University and was a CIHR Postdoctoral Fellow in the Program in Neurosciences and Mental Health at The Hospital for Sick Children. Her area of specialization was the influence of epigenetic regulatory mechanisms on cognitive development and behaviour. She has worked and published extensively in genetic communications, helping scientists and non-scientists engage in informed dialogue and decision-making on the basis of genetic information. In senior strategic and operational research administration positions for over 10 years, Lisa has developed corporate and divisional strategic plans, led teams through the completion of large strategic projects, and implemented operational systems and procedures to support effective management of the research enterprise. An exceptional corporate change agent, Lisa has driven development in the strategic and functional capacity necessary to enable knowledge translation, and facilitated research integration with practice across healthcare, legal and academic settings.



Bettina Hamelin

President and CEO, Ontario Genomics

Bettina Hamelin (PharmD, EMBA) has more than 15 years of international experience in the pharmaceutical industry as well as 10 years of experience as a tenured professor at the Faculty of Pharmacy at Université Laval. Prior to assuming her current role as President and CEO of Ontario Genomics, Bettina served as Vice-President of NSERC's Research Partnerships Directorate. She has also held a variety of leadership positions at Pfizer Canada. She is known for pioneering novel public-private partnership models, and breaking down barriers between federal, provincial and private sector stakeholders. Bettina holds a B.Sc. in pharmacy and a Doctor of Pharmacy from the University of Kentucky, U.S. and an EMBA in Healthcare from the UBC.



Jesse Hirsh

Futurist & Digital Strategist

Jesse owns and operates Metaviews Media Management Ltd., which focuses on research and consulting around new media business models, big data, and the strategic use of social media. He is also a co-founder of the Academy of the Impossible, a peer to peer lifelong learning facility. Because of the impact technology has on our relationship with the world, Jesse believes that it should be used in responsible and creative ways. Jesse is also a member of the Advisory Council for the Certificate in Machine Learning at York University's School of Continuing Studies. Jesse was educated at the McLuhan Program at the University of Toronto and he also recently completed a Masters degree at Ryerson University focusing on algorithms and predictive analytics.



Raphael (Rafi) Hofstein

Board Chair, Clinical Trials Ontario; President and CEO, MaRS Innovation

Dr. Raphael Hofstein joined MaRS Innovation as President & CEO in 2009, the year of the organization's inception. Under Dr. Hofstein's leadership, MaRS Innovation has incorporated over 50 startup companies; attracted over \$300M in seed funding; and has become a key leader in bringing global industry focus on Toronto as a place of important research and commercialization activities. Dr. Hofstein is a co-founder and director of BiolineRx in Israel (listed on NASDAQ), and of Triphase Accelerator Corporation, Canada's largest oncology oriented accelerator. Dr. Hofstein is a member of the Executive Committee of Life Science Ontario, and is the Chair of the Board of Clinical Trials Ontario. Dr. Hofstein received his PhD in Life Sciences and Chemistry from the Weizmann Institute of Science in Israel and completed post-doctoral training and research at the Harvard Medical School in Boston.



Michael Israels

Chief Financial Officer, CCRM

Michael Israels is the Chief Financial Officer of the Centre for Commercialization of Regenerative Medicine (CCRM). Prior to joining CCRM, Michael was a Management Consultant at Ernst & Young LLP, President of BEST Funds, a Toronto-based venture capital firm, and CEO Of Convexus Managed Services Inc., a start-up investment fund administration company. As CFO, Michael is responsible for overseeing finance, administrative, facility & IT activities, the creation and support of start-up regenerative medicine companies, risk management activities, sourcing of risk capital, corporate development supporting CCRM's growth strategy, and development of investment funding vehicles.



Michael Jackson

Leader, Public Health & US Elections, Amazon Web Services

Michael (MJ) Jackson leads Public Health and US Elections businesses at Amazon Web Services (AWS). He directs an agile team that commercializes mission-critical cloud offerings for addressing the unique needs of state and local governments. Since joining AWS in 2016, Jackson has successfully launched, scaled, and led multiple vertical industry businesses that drive social impact in highly regulated environments, resulting in seamless enterprise adoption, effective digital transformations, and unparalleled customer experiences. Prior to joining AWS, Jackson served as General Manager of Consumer Health at Intel Corporation and as Director of Healthcare & Digital Government at Adobe Systems. Jackson earned an MBA and a Bachelor's degree in Management Information Systems from the University of Baltimore. He is also a proud veteran of the US Coast Guard and serves on the Board of Directors at Health Care for the Homeless, a non-profit organization in Baltimore, MD.



Peter Jones

Industry Lead – Canadian Healthcare, Microsoft Canada

As Healthcare Industry Lead for Microsoft Canada, Peter Jones is responsible for developing the strategy vision of modern healthcare for the Canadian marketplace. Working closely with the Microsoft Worldwide Healthcare team, Peter is deeply enriched in the best practices of healthcare digital transformation that is being practiced by healthcare industry leaders around the globe. Peter's mandate is to help clients improve their clinical and operational performance by leveraging Microsoft solutions for healthcare data and records management, advanced analytics, and big data, while remaining compliant. Peter joined Microsoft nearly 20 years ago and has been focused on the healthcare industry for over 10 years. He is actively involved in a number Health Informatics groups such as COACH, CHIEF (Advisor), and is an active ITAC Health board member.



Kris Klein

Partner, nNovation LLP

Kris Klein, CIPP/C, CIPM, FIP, has more than two decades of experience in the federal regulatory arena, which he gained in both the public and private sectors in Canada. He is also one of the country's leading experts on the application of the Access to Information Act, the Privacy Act and the Personal Information Protection and Electronic Documents Act. Prior to founding nNovationLLP, Klein practiced exclusively in the area of privacy law for the Privacy Commissioner of Canada, where he advised the Commissioner and senior officials on legal, policy and strategic positions available in privacy matters. In addition, he interacted, negotiated and settled complaints with private sector organizations facing complaints about privacy issues. Klein has written extensively on the subject of technology, theories of anonymity (de-identification of data), authentication systems and health privacy issues. He currently teaches the privacy law course at the University of Ottawa Law School.



Carole Légaré

Director, Office of Clinical Trials, Health Products and Food Branch, Health Canada

Dr. Carole Légaré (BSc, MD, CCFP, Cert PE & PV) completed her medical training at the University of Ottawa, and her postgraduate pharmacoepidemiology and pharmacovigilance training at the London School of Hygiene and Tropical Medicine in the UK. After gaining experience in clinical practice and public health, she joined Health Canada in 2002 where she initially worked in pharmacovigilance. She also worked as a senior medical advisor for the Centre for Biologics Evaluation during the H1N1 influenza pandemic. In 2013, she joined the Therapeutic Products Directorate as the Director of the Office of Clinical Trials, where she oversees all activities related to the approval and pharmacovigilance of clinical trials involving pharmaceuticals. She is currently a member of the ICH E8 working group on General Considerations for Clinical Studies.



Susan Marlin

President and CEO, Clinical Trials Ontario

Susan Marlin is the President and CEO of Clinical Trials Ontario (CTO), an organization established in 2012 to improve the environment for conducting clinical trials. Prior to joining CTO she was the Associate Vice-Principal of Research at Queen's University and worked for many years with the National Cancer Institute of Canada Clinical Trials Group. Susan has engaged in research ethics over the years serving on research ethics boards. She was President of the Canadian Association of Research Ethics Boards and is currently a member of several boards and committees supporting clinical research and innovation in health care.



Drew Memmott

Senior Vice President for Research Administration, Dana-Farber Cancer Institute

Drew Memmott is currently the Senior Vice President for Research Administration at Dana-Farber Cancer Institute and Associate Director for Administration for the Dana-Farber/Harvard Cancer Center, a National Cancer Institute (NCI) designated Comprehensive Cancer Center comprised of five Harvard-affiliated teaching hospitals and two Harvard biomedical schools. He is the senior administrative leader for all aspects of research at DFCI and the DF/HCC consortium. In his role as SVP he is responsible for oversight of the research administrative infrastructure and clinical research operations. In his role as Associate Director for Administration for DF/HCC he oversees the administration of the DF/HCC Cancer Center Support Grant and its associated operational requirements including administration, shared resources, and clinical research support. Prior to DFCI, Drew served as Associate Director for Administration for the Mayo Clinic Comprehensive Cancer Center and as Director of Research Administration at Columbia University Medical Center.



Brad Millson

Sr. Principal, Health Access and Outcomes, IQVIA Canada

Brad leads projects to deliver real world evidence solutions, medical and market access strategy for the pharmaceutical industry and its stakeholders. Brad has almost 20 years of experience in the Life Sciences industry across government and private sectors in Canada and globally. His interests include developing innovative approaches to leveraging "big" healthcare datasets to answer core questions about value and outcomes in the healthcare system. Prior to joining IQVIA, he led the investment attraction function for Life Sciences at the Department of Foreign Affairs and International Trade. He also spent several years in the US at a leading biotech strategy consulting firm developing solutions in new product development & launch, marketing, sales, and business development. He is a Dean's List graduate of the MBS program (integrated MSc Biotech + MBA) at Keck Graduate Institute in Claremont, California, and holds a B.Sc. in Physiology from McGill University.



Anne Mullin

Engagement Leader, Shift Health

Dr. Anne Mullin works with leading decision-makers across the health and life sciences sector to amplify the impact of biomedical discoveries and healthcare innovations on the health and wellbeing of populations in both developed and developing countries. Anne's collaborative approach to working with clients and rich academic track record in the study of infectious disease have supported the sustainability and success of numerous international product development consortia, allowed both industry and academic partners to manage risk of high-impact clinical trials, and helped clients from industry, academia and the not-for-profit sector attract capital, establish partnerships and drive innovation. Having led engagements in North America, Europe, Southeast Asia and Africa, Anne's client base spans the globe.



Frank Naus

Chief Operating Officer, Allphase Clinical Research Inc.

Dr. Frank Naus is the Chief Operating Officer of Allphase Clinical Research Inc., a Canadian CRO headquartered in Ottawa, Ontario. Frank earned his Doctorate in Business Administration from Walden University and has an MBA from Wilfrid Laurier University and MSc and BSc degrees in Applied Health Sciences from the University of Waterloo. Frank started his career in the pharmaceutical and clinical research industry. Prior to joining Allphase, he was Vice President Research at Hamilton Health Sciences.



Frances A Shepherd

Cancer Clinical Research Unit, Princess Margaret Cancer Centre

Dr. Shepherd is a Senior Staff Physician at Princess Margaret Cancer Centre in Toronto, where she holds the Scott Taylor Chair in Lung Cancer Research. She is a Full Professor of Medicine at the University of Toronto and served as the University Division Director for Medical Oncology from 1997 to 2003. Dr. Shepherd served as Chair of the Lung Cancer Committee of the National Cancer Institute of Canada Clinical Trials Group for 19 years, was President of International Association for the Study of Lung Cancer from 2003 to 2005, and has been a member of the Boards of Directors of American Society of Clinical Oncology and the European Organisation for Research and Treatment of Cancer. Dr. Shepherd has designed and led more than 100 clinical trials over the past three decades and her studies have changed treatment and outcomes for patients with lung cancer at a global level. She has mentored more than 40 post-doctoral research fellows and authored or co-authored more than 550 peer-reviewed publications and 35 book chapters. In 2015, she was made an Officer of the Order of Canada and in 2018 she was awarded the prestigious Canada Gairdner Wightman Award.



Andy Smith

President and CEO, Sunnybrook Health Sciences Centre

Dr. Andy J. Smith (MD, MSc, FRCSC, FACS) is the President and Chief Executive Officer of Sunnybrook Health Sciences Centre in Toronto, Ontario. In addition, he is a Professor of Surgery at the University of Toronto. He completed medical school, including a Masters of Science, and General Surgery residency at the University of Toronto. He also completed a Surgical Oncology Fellowship at Memorial Sloan – Kettering Cancer Center in New York. Upon returning to Canada, he established himself as a leader in the management of colorectal cancer. He has served as Head of the Division of General Surgery at Sunnybrook, Chair of the Division of General Surgery at the University of Toronto and Chief of the Odette Cancer Program and Regional Vice President for Cancer Care Ontario. Most recently, Dr. Smith has served Sunnybrook as its Executive Vice President, Chief Medical Executive.



Sheila Sprague

Assistant Professor, McMaster University Department of Surgery

Dr. Sheila Sprague is a clinical researcher with expertise in the design and conduct of large randomized controlled trials, observational studies, systematic reviews, and scoping reviews. She obtained a Doctorate Degree in Medical Science from the University of Amsterdam and a Master of Science Degree in Health Research Methodology from McMaster University. She is an Assistant Professor in the Department of Surgery and serves as an Associate Faculty Member in the Department of Health Research Methods, Evidence, and Impact at McMaster University. She also serves as the Associate Director at the Centre for Evidence-Based Orthopaedics at McMaster University. Her research focusses on improving the care of fracture patients.



Alison Symington

Strategic Life Science Consultant

Dr. Alison Symington provides consultancy services to a variety of industry and academic clients in the area of Life Science strategy, including proposal development and particularly at the interface of academia and industry. Previously Alison was the Vice President, Research and Corporate Development at Ontario Genomics where she was responsible for the development and management of large-scale genomics projects as well as external stakeholder engagement. Prior to joining OGI, Alison was Executive Director of Biotechnology Education Canada. Alison was also a professor and program coordinator at Seneca College's School of Biological Sciences and Applied Chemistry. Before joining Seneca College, she was the Manager of Viral Development Laboratory and a research scientist at Sanofi Pasteur where she worked on the development and scale up of several new vaccines in clinical development.



Monica Taljaard

Senior Scientist, Clinical Epidemiology Program, Ottawa Hospital Research Institute

Monica Taljaard is a Senior Scientist in the Clinical Epidemiology Program at the Ottawa Hospital Research Institute (OHRI) and Associate Professor in the School of Epidemiology and Public Health at the University of Ottawa. She received her PhD degree in Epidemiology and Biostatistics at Western University in 2006. Her main research interests are in the design, analysis and ethics of cluster randomized trials. As a methodologist with the Ottawa Methods Centre, she works with clinicians and researchers from a variety of disciplines and medical specialties in the design and analysis of cluster randomized trials, standard clinical trials, and observational studies. She supervises MSc and PhD students in Epidemiology and teaches Biostatistics courses at the University of Ottawa.



Nadia Tanel

Director, Research Operations, Holland Bloorview Kids Rehabilitation Hospital

Nadia holds a BA in Psychology from Western University, a MEd in Educational Psychology from the University of Alberta and a Masters Certificate in Healthcare Management from the Schulich School of Business. She is a Psychometrist by training and started her career working in autism research managing intervention and randomized clinical trials. Nadia is passionate about family engagement in the life cycle of research, from idea conception to knowledge translation. She was involved in the development of the Family Engagement in Research initiative at Holland Bloorview and co-chairs the Family Engagement in Research Committee.



Nina Tangri

MPP, Mississauga-Streetsville

Nina Tangri is the Member of Provincial Parliament for Mississauga-Streetsville and a tireless advocate for improving the welfare of the community and all Ontarians. To aid in improving healthcare, she has served as Vice-Chair on the Board of Directors at the Credit Valley Hospital in Mississauga and as a cabinet member of Erinoak Kids, Ontario's largest treatment centre for children living with disabilities. A supporter of sports and cultural clubs, Nina volunteers within her community and beyond. Nina has been awarded the Global Peace and Friendship Award, the National MacDonald Cartier award for volunteer work and the Queen's Diamond Jubilee Award. Professionally, Nina has over 30 years experience in financial management. Until her election to Ontario's 42nd Parliament on June 7th 2018, she was the CEO of Tangri Insurance & Financial Group, and President of Tangri-BMT Insurance Brokers. Nina serves as Chair of the Standing Committee on Social Policy, mandated with reviewing policy related to healthcare, education and post-secondary training, seniors, accessibility, and social services. She continues to enjoy meeting with community members and businesses of Mississauga-Streetsville to learn how to make life better for Ontarians.



Ray Truant

Chair of the Scientific Advisory Board, Huntington Society of Canada

Dr. Truant was appointed Assistant Professor in the Department of Biochemistry at McMaster University in 1999 where he started new projects on polyglutamine diseases, focusing on Huntington's Disease. In 2001, he won the CIHR New Scientist award, and in 2010 he was promoted to full Professor in Biochemistry and Biomedical Sciences. He has served as Chair of the Scientific Advisory Board of the Huntington Society of Canada since 2007. Dr. Truant is a recipient of the 2012 Queen Elizabeth II Diamond Jubilee Medal and the 2014 Michael Wright Community Leadership Award. The Truant lab is in an academic setting, but highly collaborative with pharmaceutical industry, biotech and clinical collaborators. Dr. Truant is on the Scientific Advisory Board of Mitokinin LLC, a biotech firm dedicated to the development of small molecules drug therapy to restore the phosphorylation of mutant Huntingtin and treat Huntington's disease.



Charles Weijer

Professor, Canada Research Chair in Bioethics, Rotman Institute of Philosophy, Western University

Charles Weijer is Professor and Canada Research Chair in Bioethics at the Rotman Institute of Philosophy at Western University in London, Canada. He is the leading expert on the ethics of randomized controlled trials. In 2008, Charles founded the Rotman Institute of Philosophy, which is dedicated to fostering collaboration between the humanities and the sciences, and served as the Institute's first director. In 2014, he received Western's Hellmuth Prize for Achievement in Research, and, in 2016, he was elected to the Royal Society of Canada.



Durhane Wong-Rieger

President and CEO, Canadian Organization for Rare Disorders

President & CEO of the Canadian Organization for Rare Disorders, Chair of the Consumer Advocare Network, President & CEO of the Institute for Optimizing Health Outcomes, Chair of Canadian Heart Patient Alliance and member of Genome Canada Steering Committee for the Rare Disease Precision Health Initiative. Internationally, she serves as Chair of Rare Disease International, Board member of Asia Pacific Rare Disease International, member of the Editorial Board of The Patient- Patient Centred Outcomes Research, member of the Global Commission to End the Diagnosis Odyssey for Rare Diseases and member of Health Technology Assessment International Patient/Citizen Involvement Interest Group. She is also a certified Health Coach. Durhane has a PhD in psychology from McGill University and was professor at the University of Windsor, Canada. She is a trainer and frequent lecturer and author of three books and many articles.



Ma'n H. Zawati

Executive Director, Centre of Genomics and Policy, Department of Human Genetics, McGill University

As Executive Director of the Centre of Genomics and Policy, and Associate Member of McGill's Biomedical Ethics Unit, Ma'n H. Zawati (LL.B., LL.M., Ph.D. (DCL)) conducts research on the legal, ethical and policy dimensions of health research and clinical care, with a special focus on biobanking, data sharing, professional liability, and the use of novel technologies in clinical and research settings. His work is interdisciplinary, drawing perspectives from law, ethics, bioinformatics, genomics, and policy. He has appeared at 100+ international conferences and symposia, and published 13 book chapters and 45+ peer-reviewed articles in leading publications. In 2015, he was awarded the Queen Elizabeth II Diamond Jubilee Scholarship and was named a Royal Society of Canada Delegate for the IAP Young Scientists of the Year international symposium. In 2014, the Young Bar Association of Montreal named him as one of its Lawyers of the Year.

Industry Concierge Innovation Showcase

Under the banner of our Industry Concierge service, Clinical Trials Ontario welcomes a select group of Ontario-based health care start-ups that are advancing health research and patient care to this year's Innovation Showcase. These companies are helping to drive a vision for better science, better connectivity and patient empowerment, and better evidence-based health care.

AI. Vali



A.I. VALI uses proprietary Machine Learning (ML) and Deep Learning (DL) techniques to analyze the data collected from medical images, such as tissue biopsies and endoscopies. Our modular A.I. tools empower our clients with accurate, reproducible and affordable platforms at a global level. These platforms have a critical impact in the early detection of cancer in order to provide the best personalized treatment model for each patient. A.I. VALI services in R&D, analytical validation, optimization, and validation for regulatory submissions, can be incorporated into the early stages of drug development through clinical trials and validation of biomarkers, or companion diagnostics. aivali.ca

Bitnobi, Inc.



Bitnobi, Inc. is a York University startup supported by MaRS Innovation and Innovation York. Bitnobi is a privacy protected, data sharing platform that allows a data provider to set the access/view limitations for end user data queries. End users can use the system to build complex or simple queries based solely on a privacy protected view of data made available to them. This enterprise software acts as a secure interface between a data provider and end users in order to provide a more efficient way of interacting with data sources without giving raw data or making copies of them. bitnobi.com

BrainFX



BrainFx combines leading neuroscience data with cutting-edge software to deliver digital, tablet-based clinical assessment tools to measure what other tests can miss. By focusing on functional cognitive performance, BrainFx tools help to better understand a patient's cognitive profile, detect mild-to-moderate dysfunction, and understand the 'what next'. Immediate reporting analyzes patient performance through multiple statistical analyses and can save time in assessing, analyzing and reporting so that more focus can be on interpretation and next steps planning. De-identified results can be donated to the Living Brain Bank; a robust normative database shared with the research community to accelerate neuroscience. brainfx.com



bridge7

bridge7 is a healthcare technology company that focuses on integrating machine learning algorithms for analyzing clinical data and medical images into clinical workflows. We have developed and clinically validated customized machine learning algorithms to enable automated decision making and visualization in radiation oncology. Our vision is to enable any healthcare institution to deliver the highest quality care by learning from previous knowledge and treatment data. bridge7.ai



CanProbe

CanProbe is a joint not-for-profit, venture between the University Health Network (UHN) and the Centre for Probe Development and Commercialization (CPDC) to create a Canadian Centre of Excellence for the development, translation, utilization and commercialization of molecular imaging probes. CanProbe manages UHN's cyclotron facility to support R&D and clinical trials with manufacturing of novel probes, both small and large molecules with a variety of radionuclides. Through the UHN and CPDC partnership, CanProbe has the expertise and know how to move innovative probe technology and new therapeutic drugs from R&D labs to pre-clinical tests to clinical use. CanProbe enhances the ability to develop novel agents and transition them to first in-human trials. imagingprobes.ca



Deep 6 AI

Identifying patients for clinical trials is a time-consuming, inefficient process. Deep 6 AI is the solution to this problem. Using AI on medical records, Deep 6 AI finds more and better-matching patients for clinical trials in minutes, not months. About 90% of all data in the world is unstructured, yet very few software tools know how to leverage the information it contains. We build applications that understand massive amounts of unstructured data at a very high speed and learn from users to single out the information that is most important to them. deep6.ai



mitoNET

mitoNET is new Canadian network of researchers, clinicians, patients and advocates, academic institutions, NGO's and industry partners working together towards a common goal: to unveil how mitochondria act as the common thread connecting most chronic diseases and, through that understanding, to transform our ability to prevent, diagnose and treat many common human diseases and revolutionize patient care. Our mission is to transform our understanding of the role of mitochondria in human health, including common chronic diseases that range from mood to metabolism. Our vision: within ten years, clinicians in Canada—and the world—will assess mitochondrial health as part of routine care. mitoNET will deliver the tools and knowledge to realize this vision. mitonet.ca



QIPCM

The QIPCM advanced Imaging Core Lab is an integral part of TECHNA, a health technology productization institute at UHN. QIPCM provides end-to-end support for imaging in clinical trials to improve consistency and reliability in complex research. QIPCM-PIPELINES help clinical investigators simplify the workflow for de-identification, transfer and centralized image collection. QIPCM-SANDBOX facilitates access and collaboration among multidisciplinary research teams working on cutting edge innovation including radiomics, AI, central review and image analysis. QIPCM-RT enables centralized radiotherapy plan review. QIPCM enforces strict privacy and quality standards in all its activities. qipcm.technainstitute.com



Self Care Catalysts

Self Care Catalysts is a patient analytics and solutions company that empowers patients to generate real world evidence while managing their personal health. They have developed a platform that allows stakeholders across the healthcare industry, including patients, care-givers, physicians, researchers and pharmaceutical industry professionals, to better understand the real day-to-day lives of patients as they navigate their health concerns. The platform collects multiple types of data to enable multi-disciplinary and multi-stakeholder research that aligns with the 21st Century Cures Act and the FDA's growing emphasis on patient-focused drug development. selfcarecatalysts.com



University of Toronto – Pharmacology & Toxicology

University of Toronto Masters students in Applied Clinical Pharmacology are available to provide value to your clinical research team during their internship placement terms. Current students are placed in numerous clinical research roles, both participant-facing and data-driven. Our training in clinical research conduct, pharmacokinetics, drug development and clinical pharmacology provides our students with the tools for success in careers involving both investigator-initiated and sponsor-initiated trials. pharmtox.utoronto.ca/acp

Contact the CTO Industry Concierge

CTO's Industry Concierge service is for any person or company looking to connect into Ontario's clinical research ecosystem to conduct a clinical or observational research study. Whether you're a large multinational pharmaceutical company or a local start-up, we can help connect you to the relevant people or resources to get your trial off the ground. Contact andrew.haller@ctontario.ca to learn more.